Azacitidine Injection Suppliers & Bulk Manufacturers
Available Forms: Injectable
Available Strengths: 100 mg/vial
Reference Brands: Vidaza®(EU & US)
Category:
Oncology Cancer Care
Azacitidine 50 mg and 100 mg Vials (brand name Vidaza®) are used in oncology to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As a hypomethylating agent, Azacitidine works by inhibiting DNA methylation, promoting the reactivation of genes that control blood cell growth. Available as subcutaneous or intravenous injections, it is vital for patients who are ineligible for intensive chemotherapy.
Azacitidine Injection is available in Injectable
and strengths such as 100 mg/vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Azacitidine Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Azacitidine Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Azacitidine 50 mg and 100 mg Vials are essential treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Available under the brand name Vidaza®, Azacitidine is a hypomethylating agent that plays a critical role in restoring normal blood cell production in patients with MDS or AML. It works by inhibiting DNA methylation, leading to the reactivation of growth-controlling genes. Azacitidine is available in subcutaneous and intravenous injection forms in 50 mg and 100 mg vials, and is crucial in oncology B2B portfolios focused on blood cancers and hematologic malignancies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing